Investors

Investor Relations

SCYNEXIS is a drug development company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as a novel oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. 

NASDAQ: SCYX
$ 2.71 -0.03 (1.10%)
Day High: 2.78
Day Low:  2.69
Volume:    92,170
12:06 PM ET on
Mar 27, 2017

Delayed ~20 min., by eSignal.